

EXHIBIT A

10/532,264	METHODS OF ISOLATING DOPAMINERGIC NEURON PRECURSOR CELLS	01-21-2010::15:29:35
------------	--	----------------------

Patent Term Adjustments

Patent Term Adjustment (PTA) for Application Number: 10/532,264

Filing or 371(c) Date:	12-28-2005	USPTO Delay (PTO) Delay (days):	371
Issue Date of Patent:	11-24-2009	Three Years:	-
Pre-Issue Petitions (days):	+0	Applicant Delay (APPL) Delay (days):	52
Post-Issue Petitions (days):	+0	Total PTA (days):	319
USPTO Adjustment(days):	+0	Explanation Of Calculations	

Patent Term Adjustment History

Date	Contents Description	PTO(Days)	APPL(Days)
11-04-2009	PTA 36 Months		
11-24-2009	Patent Issue Date Used in PTA Calculation = end of "B" Delay		
10-16-2009	Dispatch to FDC		
10-14-2009	Application Is Considered Ready for Issue		
10-08-2009	Issue Fee Payment Verified		
10-08-2009	Issue Fee Payment Received		
08-03-2009	Sequence Forwarded to Pubs on Tape		
07-13-2009	Mail Notice of Allowance		
07-10-2009	Document Verification		
07-10-2009	Notice of Allowance Data Verification Completed		
07-10-2009	Case Docketed to Examiner in GAU		
07-10-2009	Examiner's Amendment Communication		
07-06-2009	Examiner Interview Summary Record (PTOL - 413)		
06-07-2009	Date Forwarded to Examiner		
04-23-2009	Response after Non-Final Action		52
04-23-2009	Request for Extension of Time - Granted		⬆
12-02-2008	Mail Non-Final Rejection		⬆
11-26-2008	Non-Final Rejection		
10-06-2008	Date Forwarded to Examiner		
09-11-2008	Response after Non-Final Action		
06-30-2008	Mail Non-Final Rejection		
06-27-2008	Non-Final Rejection		
03-03-2008	Reference capture on IDS		
03-03-2008	Information Disclosure Statement (IDS) Filed		
01-24-2008	Information Disclosure Statement considered		
12-28-2007	Information Disclosure Statement considered		
10-10-2007	Information Disclosure Statement considered		
12-28-2005	Information Disclosure Statement considered		
02-10-2006	Information Disclosure Statement considered		
01-30-2006	Information Disclosure Statement considered		
03-03-2008	Information Disclosure Statement considered		

EXHIBIT A -- cont.

04-25-2008	Date Forwarded to Examiner	
04-03-2008	Response to Election / Restriction Filed	
03-05-2008	Mail Restriction Requirement	371
03-03-2008	Information Disclosure Statement (IDS) Filed	⬆
01-24-2008	Electronic Information Disclosure Statement	⬆
01-24-2008	Information Disclosure Statement (IDS) Filed	⬆
02-26-2008	Requirement for Restriction / Election	⬆
12-28-2007	Information Disclosure Statement (IDS) Filed	⬆
01-24-2008	Reference capture on IDS	⬆
01-24-2008	Information Disclosure Statement (IDS) Filed	⬆
01-24-2008	Information Disclosure Statement (IDS) Filed	⬆
12-28-2007	Information Disclosure Statement (IDS) Filed	⬆
10-10-2007	Information Disclosure Statement (IDS) Filed	⬆
10-10-2007	Information Disclosure Statement (IDS) Filed	⬆
03-01-2007	Preliminary Amendment	⬆
01-30-2006	Information Disclosure Statement (IDS) Filed	⬆
01-30-2006	Information Disclosure Statement (IDS) Filed	⬆
08-31-2006	IFW TSS Processing by Tech Center Complete	⬆
08-31-2006	Case Docketed to Examiner in GAU	⬆
12-28-2005	Preliminary Amendment	⬆
08-18-2006	Miscellaneous Incoming Letter	⬆
02-10-2006	Reference capture on IDS	⬆
12-28-2005	Reference capture on IDS	⬆
02-10-2006	Information Disclosure Statement (IDS) Filed	⬆
02-10-2006	Information Disclosure Statement (IDS) Filed	⬆
12-28-2005	Information Disclosure Statement (IDS) Filed	⬆
12-28-2005	Information Disclosure Statement (IDS) Filed	⬆
07-13-2006	Cleared by OIPE CSR	⬆
07-13-2006	Cleared by OIPE CSR	⬆
07-13-2006	Cleared by OIPE CSR	⬆
12-28-2005	371 Completion Date	← 371(c) date ⬆
07-06-2006	Application Dispatched from OIPE	
07-06-2006	Notice of DO/EO Acceptance Mailed	
12-28-2005	Additional Application Filing Fees	
12-28-2005	Information Disclosure Statements	<u>Note:</u>
12-28-2005	A statement by one or more inventors satisfying the requirement under 35 USC 115, Oath of the Applic	371(b) expiration is 4/22/2005

Close Window

"A" Delay: 2/28/2007 thru 3/5/2008 = 371 days

"B" Delay: 4/23/2008 thru 11/24/2009 = 581 days



US00762270B2

(12) **United States Patent**
Nakagawa et al.

(10) **Patent No.:** US 7,622,270 B2
(45) **Date of Patent:** Nov. 24, 2009

(54) **METHODS OF ISOLATING DOPAMINERGIC NEURON PRECURSOR CELLS**

WO WO 2004/065599 A1 8/2004

(75) **Inventors:** Yasuko Nakagawa, Kyoto (JP); Yuichi Ono, Kyoto (JP); Yoshimasa Sakamoto, Kyoto (JP); Eri Mizuhara, Kyoto (JP); Tomoya Nakatani, Kyoto (JP); Yoshimi Takai, Kobe (JP)

OTHER PUBLICATIONS

(73) **Assignee:** Eisai R&D Management Co., Ltd., Tokyo (JP)

(*) **Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 319 days.

(21) **Appl. No.:** 10/532,264

(22) **PCT Filed:** Oct. 21, 2003

(86) **PCT No.:** PCT/JP03/13420

§ 371 (c)(1),
(2), (4) **Date:** Dec. 28, 2005

(87) **PCT Pub. No.:** WO2004/038018

PCT Pub. Date: May 6, 2004

(65) **Prior Publication Data**
US 2006/0239978 A1 Oct. 26, 2006

(30) **Foreign Application Priority Data**
Oct. 22, 2002 (JP) 2002-307573

(51) **Int. Cl.**
G01N 33/567 (2006.01)
C07K 16/28 (2006.01)

(52) **U.S. Cl.:** 435/7.21; 530/387.9

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,304,145 B2 12/2007 Goddard et al.
2002/0068045 A1 6/2002 Rostinoff et al.
2002/0127584 A1 9/2002 Baker et al.
2002/0155423 A1 10/2002 Okano et al.
2003/0036150 A1 2/2003 Baker et al.
2003/0109039 A1* 6/2003 Buck et al. 435/368
2004/0241170 A1* 12/2004 Jensen et al. 424/178.1
2007/0254281 A1 11/2007 Ono et al.

FOREIGN PATENT DOCUMENTS

CA 2,315,538 A1 7/1999
JP 2001-526884 A 12/2001
WO WO 94/23754 A1 10/1994
WO WO 01/92482 A1 12/2001
WO WO 01/98360 A2 12/2001
WO WO 01/98360 A3 12/2001

Sun (2003) *Genomics* 82(2):130-142.*
Genbank Accession No. AF296764, "Mus musculus nephrin (Nphs1) gene, 5' flanking region, 5' UTR.", Aug. 16, 2000.
Genbank Accession No. AC002133, "Human DNA from chromosome 19 cosmid R33502, genomic sequence", Jun. 3, 1997.
Genbank Accession No. BC052773, "Mus musculus kin of IRRE like 2 (Drosophila), mRNA (cDNA clone MGC:56936 Image:6314924)", May 23, 2003.
Björklund, Lars M. et al.; "Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model", *PNAS*, Feb. 19, 2002; pp. 2344-2349; vol. 99, No. 4.
Björklund, Anders et al.; "Neural transplantation for the treatment of Parkinson's disease", *The Lancet: Neurology*, Jul. 2003; pp. 437-445; vol. 2.
Kim, Tai Eun et al.; "Cloning and cell type-specific regulation of the human tyrosine hydroxylase gene promoter", *Biochemical and Biophysical Research Communications*; 2003; pp. 1123-1131; vol. 312.
Yan, Jun et al.; "Ascorbic acid increases the yield of dopaminergic neurons derived from basic fibroblast growth factor expanded mesencephalic precursors", *Journal of Neurochemistry*; 2001; pp. 307-311; vol. 76.
Alberts, B. et al., *Molecular Biology of the Cell*, pp. 104-111, Third Edition (1994).
Huber, Tobias B. et al.; "The carboxyl terminus of Neph family members binds to the PDZ domain protein zohal occludens-1", *The Journal of Biological Chemistry*, Apr. 11, 2003; pp. 13417-13421; vol. 278, No. 15.

Ihalmo, Pekka et al.; "Filtrin is a novel member of nephrin-like proteins", *Biochemical and Biophysical Research Communications*; 2003; pp. 364-370; vol. 300.

Kawasaki, Hiroshi et al.; "Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity", *Neuron*, Oct. 2000; pp. 31-40; vol. 28.

Kim, Jong-Hoon et al.; "Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease", *Nature*, Jul. 4, 2002; pp. 50-56; vol. 418.

Kordower, J. H. et al.; "Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease", *N. Engl. J. Med.*, Apr. 27, 1995; pp. 1118-1124; vol. 332, No. 17.

Lisitsyn, N. A.; "Representational difference analysis: finding the differences between genomes", *Trends Genet.*, Aug. 1995; pp. 303-307; vol. 11, No. 8.

(Continued)

Primary Examiner—Daniel E. Kolker
(74) **Attorney, Agent, or Firm**—Townsend and Townsend and Crew LLP

(57) **ABSTRACT**

A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.

EXHIBIT C

PTA Calculation Table -- Wyeth version

Client Matter No. 082368-004000US

Application No. 10/532,264

For: *GENE EXPRESSED SPECIFICALLY IN DOPAMINE-PRODUCING NEURON PRECURSOR
CELLS AFTER TERMINATION OF DIVISION*

Additions to the PTA (PTO)	Deductions to the PTA (Applicant)
371(b) expiration: 4/22/2005 371 (c) date: 12/28/2005 14 month Deadline: 2/28/2007 1 st R/R: 3/5/2008 Over 14 months: <u>+ 371 days ("A")</u> 3-year deadline from 371(b) date: 4/22/2008 Date Patent Issued: 11/24/2009 Date of RCE: N/A -- none filed Over 3 years <u>+581 days ("B")</u> Overlap: N/A	Date of R/R: 3/5/2008 Date of Response: 4/3/2008 Over 3 months: 0 days Date of OA: 6/30/2008 Date of Response: 9/11/2008 Over 3 months: 0 days Date of OA: 12/2/2008 Date of Response: 4/23/2009 Over 3 months: <u>-52 days</u> Date of Not. Allow: 7/13/2009 Issue Fee paid: 10/8/2009 Over 3 months: 0 days
"A" PTA: +371 days "B" PTA: +581 days	
(A + B)**- overlap days= +952 days	Applicant Delay: - 52 days
non-Wyeth/371 error PTA: 529 days Wyeth + 371 error PTA: 900 days	

***A" + "B" dates cannot occur on the same date.